Skip to content
Open access

CLINICAL AND TECHNICAL OUTCOMES OF TRANSARTERIAL CHEMOEMBOLIZATION (TACE) FOR HEPATOCELLULAR CARCINOMA: A SINGLE-CENTER EXPERIENCE

Oct 2026 · Eurasian Journal of Oncology and Radiology · 0 citations

TL;DR

Elevated AFP and PIVKA-II levels, multifocal involvement, and tumor size ≥ 5 cm were associated with advanced disease and high technical success and acceptable short-term safety of transarterial chemoembolization demonstrated high technical success and acceptable short-term safety.

Abstract

Relevance: Hepatocellular carcinoma (HCC) accounts for 75-90% of primary liver malignancies and is the third leading cause of cancer-related mortality worldwide. Transarterial chemoembolization (TACE) is standard treatment for intermediate-stage disease. The study aimed to evaluate the clinical and technical outcomes and short-term safety of transarterial chemoembolization in patients with hepatocellular carcinoma treated at a specialized center. Materials and Methods: This retrospective single-center study included 101 patients with HCC who underwent TACE at the A.N. Syzganov National Scientific Center of Surgery (Almaty, Kazakhstan) between 2023 and 2026. We used IBM SPSS Statistics 26.0 to analyze clinical, tumor, laboratory, procedural, and immediate outcome data. We used odds ratios with 95% confidence intervals to assess associations; we considered p < 0.05 significant. Results: The mean age was 63.8 ± 9.7 years, and 67.3% of patients were male. HCV infection was the most common underlying liver disease (53.5%). BCLC stage B disease was present in 64.4% and Child-Pugh class A liver function in 70.3%. Technical success was achieved in 99.0% of cases; mean procedure duration was 63.7 ± 24.8 minutes. After TACE, total bilirubin (p = 0.041), ALT, and AST (p < 0.001) increased significantly, whereas coagulation and renal function remained stable (p > 0.05). AFP > 400 ng/mL, PIVKA-II > 200 mAU/mL, multifocal liver involvement, and tumor size ≥ 5 cm were associated with more advanced tumor burden. Conclusion: TACE demonstrated high technical success and acceptable short-term safety. Elevated AFP and PIVKA-II levels, multifocal involvement, and tumor size ≥ 5 cm were associated with advanced disease. Because we did not assess objective response by mRECIST or long-term oncological outcomes, these findings primarily reflect technical and immediate outcomes.

Read PDF

Similar papers

Sep 2026

Impact of adjuvant transarterial chemoembolization on survival following hepatectomy for subcapsular hepatocellular carcinoma: A propensity score-matched study.

BACKGROUND Subcapsular hepatocellular carcinoma (HCC) is prone to postoperative recurrence, possibly related to tumor cell dissemination during surgery. Despite this high-risk feature, the role of routine postoperative adjuvant transarterial chemoembolization (TACE) remains controversial. This study evaluated adjuvant...

Q. Kong, Hao-Jia Wang, Jia-Hui Yang et al. · 0 citations
Oct 2026

Transarterial Radioembolization for Hepatocellular Carcinoma Beyond the Up-to-Seven Criteria: A Single-Center Retrospective Cohort Study.

In this single-center retrospective cohort of patients with HCC beyond the Up-to-Seven criteria, favorable tumor control and survival outcomes were observed after TARE, and 22.3% of patients subsequently underwent curative-intent surgery.

T. W. Baek, Gun Ha Kim, Eunbyeol Ko et al. · 0 citations
Open access Sep 2026

Long-Term Outcomes of Interventional Treatments for Lung Cancer Liver Metastases: Transarterial Chemoembolization and Microwave Ablation

Purpose: The aim of this study was to evaluate the long-term results of transarterial chemoembolization (TACE) and microwave ablation (MWA) as locoregional interventional treatments for lung cancer liver metastases (LCLM) in different protocols and settings. Material and Methods: A total of 56 patients (31 males and 25...

T. Vogl, Angeliki M. Angelopoulou, T. Gruber-Rouh et al. · 0 citations
Open access Nov 2026

Value of Magnetic Resonance Imaging in Evaluating the Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma at E Hospital

Abstract: A retrospective study of 32 patients with primary liver cancer treated with transarterial chemoembolization (TACE) who underwent 1.5 Tesla magnetic resonance imaging (MRI) before and 1 month after intervention at E Hospital from May 2026 to October 2026 showed the following results: the mean age was 69.66 ± 8...

P. Nguyen, S. Nguyễn · 0 citations
Open access Oct 2026

Frailty After Transarterial Chemoembolization for Hepatocellular Carcinoma: A Cross-Sectional Study of Incidence and Associated Factors

A significant number of HCC patients could have frailty after TACE, and advanced age, female sex, poor nutrition, low Barthel Index, high SII, and low hemoglobin level were associated with frailty in these patients.

Yu-Ying Lin, Duo Qian, Bing-Xin Jiang et al. · 0 citations
Open access Sep 2026

Management and Clinical Outcomes of Liver Hemangiomas: A Retrospective Comparative Study of Transcatheter Arterial Embolization and Surgery

Background and Objectives: Hemangiomas are the most common benign tumors of the liver. Surgical options such as enucleation, segmentectomy, and hepatectomy are the primary treatment choices, though the morbidity and complication rates remain high. Transcatheter arterial embolization (TAE) has emerged as a safe and effe...

S. Ergün, Fadime Kutluk, Rauf Hamid et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.